Aptose Biosciences Inc., of San Diego and Toronto, said the FDA granted orphan drug designation to its pan-FLT3/pan-BTK inhibitor, CG'806, for acute myeloid leukemia. The company intends to begin clinical trials in both acute myeloid leukemia and B-cell malignancies in 2018.